These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 23846996)

  • 41. A randomized controlled trial of pemoline for attention-deficit/hyperactivity disorder in substance-abusing adolescents.
    Riggs PD; Hall SK; Mikulich-Gilbertson SK; Lohman M; Kayser A
    J Am Acad Child Adolesc Psychiatry; 2004 Apr; 43(4):420-9. PubMed ID: 15187802
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Attention-deficit/hyperactivity disorder and substance abuse.
    Harstad E; Levy S;
    Pediatrics; 2014 Jul; 134(1):e293-301. PubMed ID: 24982106
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The adolescent outcome of children with attention deficit hyperactivity disorder treated with methylphenidate or methylphenidate combined with multimodal behaviour therapy: results of a naturalistic follow-up study.
    van der Oord S; Prins PJ; Oosterlaan J; Emmelkamp PM
    Clin Psychol Psychother; 2012; 19(3):270-8. PubMed ID: 21404369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Stimulant-responsive and stimulant-refractory aggressive behavior among children with ADHD.
    Blader JC; Pliszka SR; Jensen PS; Schooler NR; Kafantaris V
    Pediatrics; 2010 Oct; 126(4):e796-806. PubMed ID: 20837589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview.
    Pliszka SR
    J Clin Psychiatry; 1998; 59 Suppl 7():50-8. PubMed ID: 9680053
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study.
    Katusic SK; Barbaresi WJ; Colligan RC; Weaver AL; Leibson CL; Jacobsen SJ
    J Child Adolesc Psychopharmacol; 2005 Oct; 15(5):764-76. PubMed ID: 16262593
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medications used in the treatment of disruptive behavior in children with FASD--a guide.
    Ozsarfati J; Koren G
    J Popul Ther Clin Pharmacol; 2015; 22(1):e59-67. PubMed ID: 25715382
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Attention-deficit/hyperactivity disorder subtypes in adolescents with comorbid substance-use disorder.
    Tamm L; Adinoff B; Nakonezny PA; Winhusen T; Riggs P
    Am J Drug Alcohol Abuse; 2012 Jan; 38(1):93-100. PubMed ID: 21834613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medication therapy for attention deficit/hyperactivity disorder is associated with lower risk of fracture: a retrospective cohort study.
    Perry BA; Archer KR; Song Y; Ma Y; Green JK; Elefteriou F; Dahir KM
    Osteoporos Int; 2016 Jul; 27(7):2223-2227. PubMed ID: 26928186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of conduct problems in the relation between Attention-Deficit Hyperactivity disorder, substance use, and gaming.
    Schoenmacker GH; Groenman AP; Sokolova E; Oosterlaan J; Rommelse N; Roeyers H; Oades RD; Faraone SV; Franke B; Heskes T; Arias Vasquez A; Claassen T; Buitelaar JK
    Eur Neuropsychopharmacol; 2020 Jan; 30():102-113. PubMed ID: 30292416
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dopamine and serotonin genetic risk scores predicting substance and nicotine use in attention deficit/hyperactivity disorder.
    Groenman AP; Greven CU; van Donkelaar MM; Schellekens A; van Hulzen KJ; Rommelse N; Hartman CA; Hoekstra PJ; Luman M; Franke B; Faraone SV; Oosterlaan J; Buitelaar JK
    Addict Biol; 2016 Jul; 21(4):915-23. PubMed ID: 25752199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Substance use and nicotine dependence in persistent, remittent, and late-onset ADHD: a 10-year longitudinal study from childhood to young adulthood.
    Ilbegi S; Groenman AP; Schellekens A; Hartman CA; Hoekstra PJ; Franke B; Faraone SV; Rommelse NNJ; Buitelaar JK
    J Neurodev Disord; 2018 Dec; 10(1):42. PubMed ID: 30587104
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Higher risk of developing mood disorders among adolescents with comorbidity of attention deficit hyperactivity disorder and disruptive behavior disorder: a nationwide prospective study.
    Chen MH; Su TP; Chen YS; Hsu JW; Huang KL; Chang WH; Chen TJ; Bai YM
    J Psychiatr Res; 2013 Aug; 47(8):1019-23. PubMed ID: 23643104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study.
    Mannuzza S; Klein RG; Moulton JL
    J Child Adolesc Psychopharmacol; 2003; 13(3):273-82. PubMed ID: 14642015
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Psychiatric comorbidity among children and adolescents with and without persistent attention-deficit hyperactivity disorder.
    Gau SS; Ni HC; Shang CY; Soong WT; Wu YY; Lin LY; Chiu YN
    Aust N Z J Psychiatry; 2010 Feb; 44(2):135-43. PubMed ID: 20113302
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Differential stimulant response on attention in children with comorbid anxiety and oppositional defiant disorder.
    Goez H; Back-Bennet O; Zelnik N
    J Child Neurol; 2007 May; 22(5):538-42. PubMed ID: 17690058
    [TBL] [Abstract][Full Text] [Related]  

  • 57. ADHD: monitoring for and managing stimulant adverse effects.
    Mercer M; Farver D
    S D Med; 2013 Dec; 66(12):511, 513. PubMed ID: 24527549
    [No Abstract]   [Full Text] [Related]  

  • 58. Emotional lability in children and adolescents with attention deficit/hyperactivity disorder (ADHD): clinical correlates and familial prevalence.
    Sobanski E; Banaschewski T; Asherson P; Buitelaar J; Chen W; Franke B; Holtmann M; Krumm B; Sergeant J; Sonuga-Barke E; Stringaris A; Taylor E; Anney R; Ebstein RP; Gill M; Miranda A; Mulas F; Oades RD; Roeyers H; Rothenberger A; Steinhausen HC; Faraone SV
    J Child Psychol Psychiatry; 2010 Aug; 51(8):915-23. PubMed ID: 20132417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing attention-deficit/hyperactivity disorder in the presence of substance use disorder.
    Upadhyaya HP
    J Clin Psychiatry; 2007; 68 Suppl 11():23-30. PubMed ID: 18307378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A review of attention-deficit/hyperactivity disorder complicated by symptoms of oppositional defiant disorder or conduct disorder.
    Connor DF; Steeber J; McBurnett K
    J Dev Behav Pediatr; 2010 Jun; 31(5):427-40. PubMed ID: 20535081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.